Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.

"Declarations Ethics approval and consent to participateAll animal experiments were performed according to a UNMC Institutional Animal Care and Use Committee (IACUC) approved protocol, #18–037-06-FC. Consent for publication:Not applicable. Competing interestsThe authors declare that they have no competing interest. Competing interests The authors declare that they have no competing interest."

"Funding This work was supported by the State of Nebraska through the Pediatric Cancer Research-Child Health Research Institute (PCRG-CHRI) Grant Funds (LB905) awarded to N. K. Chaturvedi, PhD. This study was partially also supported by the Team Jack Foundation Power 5 Grant awarded to N. K. Chaturvedi, PhD. These fundings had no role in the study design, data collection and analysis, interpretation of the data, decision to publish, or writing the manuscript."